List of all original works

(66.)

Neoadjuvant trastuzumab, pertuzumab and docetaxel versus trastuzumab emtansine in patients with HER2-positive breast cancer (PREDIX HER2): a randomised, open-label, phase 2 trial

Hatschek T, Foukakis T, Bjöhle J, Lekberg T, Fredholm H, Elinder E, Bosch A, Pekar G, Lindman H, Schiza A, Einbeigi Z, Adra J, Andersson A, Carlsson L, Dreifaldt A, Isaksson-Friman E, Agartz S, Azavedo E, Grybäck P, Hellström M, Johansson M, Maes C, Zerdes I, Hartman J, Brandberg Y, Bergh J.

JAMA Oncology, in press April 2021.

(65.)

Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study.

Acs B, Fredriksson I, Rönnlund C, Hagerling C, Ehinger A, Kovács A, Røge R, Bergh J, Hartman J.

Cancers (Basel). 2021 Mar 9;13(5):1166.

https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/33803148/

 

(64.)

Molecular analyses of triple-negative breast cancer in the young and elderly.

Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.

Breast Cancer Res. 2021 Feb 10;23(1):20

https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/33568222/

(63.)

Wolfsberger J, Sakil HAM, Zhou L, van Bree N, Baldisseri E, de Souza Ferreira S, Zubillaga V, Stantic M, Fritz N, Hartman J, Rolny C, Wilhelm MT.

Proc Natl Acad Sci U S A. 2021 Mar 9;118(10)

https://pubmed-ncbi-nlm-nih-gov.proxy.kib.ki.se/33649219/

(62.)

Glodzik D, Bosch A, Hartman J, Aine M, Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus E, Holm K, Häkkinen J, Hegardt C, Saal LH, Larsson C, Malmberg M, Rydén L, Ehinger A, Loman N, Kvist A, Ehrencrona H, Nik-Zainal S, Borg Å, Staaf J.

Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.

Nat Commun. 2020 Jul 27;11(1):3747.

https://pubmed.ncbi.nlm.nih.gov/32719340/

 

(61.)

Singh M, Zhou X, Chen X, Santos GS, Peuget S, Cheng Q, Rihani A, Arnér ESJ, Hartman J, Selivanova G.

Identification and targeting of selective vulnerability rendered by tamoxifen resistance.

Breast Cancer Res. 2020 Jul 29;22(1):80

https://pubmed.ncbi.nlm.nih.gov/32727562/

(60.)

Hases L, Indukuri R, Birgersson M, Nguyen-Vu T, Lozano R, Saxena A, Hartman J, Frasor J, Gustafsson JÅ, Katajisto P, Archer A, Williams C.

Intestinal estrogen receptor beta suppresses colon inflammation and tumorigenesis in both sexes.

Cancer Lett. 2020 Jul 22,

https://pubmed.ncbi.nlm.nih.gov/32711097/

(59.)

Tamborero D, Dienstmann R, Rachid MH, Boekel J, Baird R, Braña I, De Petris L, Yachnin J, Massard C, Opdam FL, Schlenk R, Vernieri C, Garralda E, Masucci M, Villalobos X, Chavarria E; Cancer Core Europe consortium, Calvo F, Fröhling S, Eggermont A, Apolone G, Voest EE, Caldas C, Tabernero J, Ernberg I, Rodon J, Lehtiö J.

Support systems to guide clinical decision-making in precision oncology: The Cancer Core Europe Molecular Tumor Board Portal.

Nat Med. 2020 Jul 6.

https://pubmed.ncbi.nlm.nih.gov/32632195/

(58.)

Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score.

Robertson S, Acs B, Lippert M, Hartman J.

Breast Cancer Res Treat. 2020 Jun 22. doi: 10.1007/s10549-020-05752-w.

https://pubmed.ncbi.nlm.nih.gov/32572716/

(57.)

Tanaka N, Kanatani S, Kaczynska D, Fukumoto K, Louhivuori L, Mizutani T, Kopper O, Kronqvist P, Robertson S, Lindh C, Kis L, Pronk R, Niwa N, Matsumoto K, Oya M, Miyakawa A, Falk A, Hartman J, Sahlgren C, Clevers H, Uhlén P.

Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies.

Nat Biomed Eng. 2020 Sep;4(9):875-888.

https://pubmed.ncbi.nlm.nih.gov/32601394/

(56.)

Amgad M, Stovgaard ES, Balslev E, Thagaard J, Chen W, Dudgeon S, Sharma A, Kerner JK, Denkert C, Yuan Y, AbdulJabbar K, Wienert S, Savas P, Voorwerk L, Beck AH, Madabhushi A, Hartman J et al.

Report on Computational Assessment of Tumor Infiltrating Lymphocytes, From the International Immuno-Oncology Biomarker Working Group

NPJ Breast Cancer. 2020 May 12;6:16.

https://pubmed.ncbi.nlm.nih.gov/32411818

(55.)

Kos Z, Roblin E, Kim RS, Salgado R et al; International Immuno-Oncology Biomarker Working Group.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer.

NPJ Breast Cancer. 2020 May 12;6:17.

https://pubmed.ncbi.nlm.nih.gov/32411819/

 

(54.)

Zerdes I, Sifakis EG, Matikas A, Chrétien S, Tobin NP, Hartman J, Rassidakis GZ, Bergh J, Foukakis T.

Programmed Death Ligand-1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease.

Mol Oncol. 2020 Mar 1.

https://www.ncbi.nlm.nih.gov/pubmed/32115850

(53.)

Peuget S, Zhu J, Sanz G, Singh M, Gaetani M, Chen X, Shi Y, Ata Saei A, Visnes T, Lindström M, Rihani A, Moyano-Galceran L, Carlson J, Hjerpe E, Joneborg U, Lehti K, Hartman J, Helleday T, Zubarev R, Selivanova G

Thermal proteome profiling identifies oxidative-dependent inhibition of the transcription of major oncogenes as a new therapeutic mechanism for select anticancer compounds.

Cancer Res. 2020 Feb 4.

https://pubmed.ncbi.nlm.nih.gov/32019870

(52.)

Langebäck A, Bacanu S, Laursen H, Mout L, Seki T, Erkens-Schulze S, Ramos AD, Berggren A, Cao Y, Hartman J, van Weerden W, Bergh J, Nordlund P, Lööf S.

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance.

Sci Rep. 2019 Dec 18;9(1):19384

https://www.ncbi.nlm.nih.gov/pubmed/31852908

(51.)

Neo SY, Yang Y, Julien R, Ma R, Chen X, Chen Z, Tobin NP, Blake E, Seitz C, Thomas R, Wagner AK, Andersson J, de Boniface J, Bergh J, Murray S, Alici E, Childs R, Johansson M, Westerberg LS, Haglund F, Hartman J, Lundqvist A.

CD73 Immune Checkpoint Defines Regulatory NK-cells within the Tumor Microenvironment.

J Clin Invest. 2020 Mar 2;130(3):1185-1198 https://www.ncbi.nlm.nih.gov/pubmed/31770109

(50.)

Langebäck A, Bacanu S, Laursen H, Mout L, Seki T, Erkens-Schulze S, Ramos AD, Berggren A, Cao Y, Hartman J, van Weerden W, Bergh J, Nordlund P, Lööf S.

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance.

Sci Rep. 2019 Dec 18;9(1):19384.

https://www.ncbi.nlm.nih.gov/pubmed/31852908

(49.)

Zhang X, Garnerone S, Nicoś M, Harbers L, Marchiò M, Simonetti M, Mirzazadeh R, Venesio T, Sapino A, Hartman J, Bienko M, Crosetto N.

CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples.

Nat Commun. 2019 Oct 18;10(1):4732.

https://www.ncbi.nlm.nih.gov/pubmed/31628304

(48.)

Costa TDF, Zhuang T, Lorent J, Turco E, Olofsson H, Masia-Balague M, Zhao M, Rabieifar P, Robertson N, Kuiper R, Sjölund J, Spiess M, Hernández-Varas P, Rabenhorst U, Roswall P, Ma R, Gong X, Hartman J, Pietras K, Adams PD, Defilippi P, Strömblad S.

PAK4 suppresses RELB to prevent senescence-like growth arrest in breast cancer.

Nat Commun. 2019 Aug 9;10(1):3589.

https://www.ncbi.nlm.nih.gov/pubmed/31399573

(47.)

Prakash V, Feenstra J F, Carson B, Dass R, Sekyrova P, Hoshino A, Petersen J, Parks M M, Guo Y, Haller K, Hashimoto A, Rundqivst H, Condeelis JS, Allis J, Drygin D, Nieto A, Andäng M, Percipalle P, Bergh  J, Adameyko I,

Ostlund-Farrants AK, Hartman J, Lyden D, Pietras K, Blanchard S, Vincent T.

De novo ribosomal RNA synthesis fuels EMT in development and disease

Nat Commun. 2019 May 8;10(1):2110

https://www.ncbi.nlm.nih.gov/pubmed/31068593

 

(46.)

Robertson S, Rönnlund C, de Boniface J, Hartman J.

Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.

Breast Cancer Res Treat. 2019 Apr;174(3):795-805

https://www.ncbi.nlm.nih.gov/pubmed/30659433

(45.)

Falato C, Taylor SK, Szulkin R, Nordblom A, Eriksson L, Sofiadis A, Fredriksson I, Hartman J, Bergh J, Foukakis T.

Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry.

Breast Cancer Res Treat. 2018 Dec;172(3):703-712

https://www.ncbi.nlm.nih.gov/pubmed/30225620

(44.)

Mutvei AP, Landor SK, Fox R, Braune EB, Tsoi YL, Phoon YP, Sahlgren C, Hartman J, Bergh J, Jin S, Lendahl U.

Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types.

Oncogene. 2018 Nov;37(46):6083-6095

https://www.ncbi.nlm.nih.gov/pubmed/29993038

(43.)

Brännström A, Rocksén D, Hartman J, Nyman N, BSc JG, Arborelius UP, Günther M.

Abdominal Aortic and Junctional Tourniquet release after 240 min is survivable and associated with small intestine and liver ischemia after porcine class II hemorrhage.

J Trauma Acute Care Surg. 2018 Jul 5.

https://www.ncbi.nlm.nih.gov/pubmed/29985233

(42.)

Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, Crosetto N, Foukakis T, Navin NE.

Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing.

Cell. 2018 May 3;173(4):879-893

https://www.ncbi.nlm.nih.gov/pubmed/29681456

(41.)

Robertson S, Stålhammar G, Darai-Ramqvist E, Rantalainen M, Tobin NP, Bergh J, Hartman J.

Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer.

J Clin Pathol. 2018 Sep;71(9):787-794

https://www.ncbi.nlm.nih.gov/pubmed/29588372

(40.)

Ullah I, Karthik GM, Alkodsi A, Kjällquist U, Stålhammar G, Lövrot J, Fuentes Martinez N, Lagergren J, Hautaniemi S, Hartman J* and Bergh J*.

*Shared authorship.

Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph-nodes

J Clin Invest. 2018 Apr 2;128(4):1355-1370

https://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pubmed/29480816

(39.)

Kjällquist U, Erlandsson R, Tobin NP, Alkodsi A, Ullah I, Stålhammar G, Karlsson E, Hatschek T, Hartman J, Linnarsson S and Bergh J.

Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs).

BMC Cancer. 2018 Feb 12;18(1):174

https://www-ncbi-nlm-nih-gov.proxy.kib.ki.se/pubmed/29433456

 

(38.)

Stålhammar G, Robertson S, Wedlund L, Lippert M, Rantalainen M, Bergh J, Hartman J.

Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer.

Histopathology. 2018 May;72(6):974-989

https://www.ncbi.nlm.nih.gov/pubmed/29220095

(37.)

Tanaka N, Kanatani S, Tomer R, Sahlgren C, Kronqvist P, Kaczynska D, Louhivuori L, Kis L, Lindh C, Mitura P, Stepulak A, Corvigno S, Hartman J, Micke P, Mezheyeuski A, Strell C, Carlson JW, Moro CF, Dahlstrand H, Östman A, Matsumoto K, Wiklund P, Oya M, Miyakawa A, Deisseroth K,  Uhlén P.

Whole-tissue biopsy phenotyping of threedimensional tumours reveals patterns of cancer heterogeneity.

Nat Biomed Eng. 2017 Oct;1(10):796-806

https://www.nature.com/articles/s41551-017-0139-0

(36.)

Karthik GM, Rantalainen M, Stålhammar G, Lövrot J, Ullah I, Alkodsi A, Ma R, Wedlund L, Lindberg J, Frisell J, Bergh J, Hartman J.

Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.

BMC Cancer. 2017 Nov 29;17(1):802.

https://www.ncbi.nlm.nih.gov/pubmed/29187174

(35.)

Liu CF, Zhang Y, Lim S, Hosaka K, Yang Y, Pavlova T, Alkasalias T, Hartman J, Jensen L, Xing XM, Wang X, Lu YT, Nie GH, Cao Y.

A zebrafish model discovers a novel mechanism of stromal fibroblast-mediated cancer metastasis.

Clin Cancer Res. 2017 Aug 15;23(16):4769-4779

https://www.ncbi.nlm.nih.gov/pubmed/28420724

(34.)

Ma R, Karthik GM, Lövrot J, Haglund F, Rosin G, Katchy A, Zhang X, Viberg L, Jan Frisell J, Williams C, Linder S, Fredriksson I and Hartman J.

Estrogen receptor b as a therapeutic target in breast cancer stem cells.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-14

https://www.ncbi.nlm.nih.gov/pubmed/28376210

(33.)

Rantalainen M, Klevebring D, Lindberg J, Ivansson E, Rosin G, Kis L, Celebioglu F, Fredriksson I, Czene K, Frisell J, Hartman J, Bergh J and Gronberg H. Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers.

Sci Rep. 2016 Nov 30;6:38037

https://www.ncbi.nlm.nih.gov/pubmed/27901097

(32.)

Villard C, Eriksson P, Kronqvist M, Lengquist M, Jorns C, Hartman J, Roy J, Hultgren R. Differential expression of sex hormone receptors in abdominal aortic aneurysms.

Maturitas. 2017 Feb;96:39-44.

https://www.ncbi.nlm.nih.gov/pubmed/28041593

 

(31.)

Hosaka K, Yang Y, Seki T, Fischer C, Dubey O, Fredlund E, Hartman J, Religa P, Morikawa H, Ishii Y, Sasahara M, Larsson O, Cossu G, Cao R, Lim S, Cao Y.

Pericyte-fibroblast transition promotes tumor growth and metastasis.

Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5618-27

http://www.ncbi.nlm.nih.gov/pubmed/27608497

(30.)

Li J, Ivansson E, Klevebring D, Tobin NP, Lindström LS, Holm J, Prochazka G, Cristando C, Palmgren J, Törnberg S, Humphreys K, Hartman J, Frisell J, Rantalainen M, Lindberg J, Hall P, Bergh J, Grönberg H, Czene K.

Molecular differences between screen-detected and interval breast cancers are largely explained by PAM50 subtypes.

Clin Cancer Res. 2017 May 15;23(10):2584-2592

http://www.ncbi.nlm.nih.gov/pubmed/27587435

(29.)

Pellegrini P, Dyczynski M, Kharaziha P, Vittoria F, Karlgren M, Buoncervello M,  Hägg-Olofsson M, Ma R, Hartman J, Pokrovskaja-Tamm K, Bajalica-Lagercrantz S,  Grander D, De Milito A

Tumor acidosis enhances autophagy inhibition by salinomycin on cancer cell lines and cancer stem cells.

Oncotarget. 2016 Jun 14;7(24):35703-35723

http://www.ncbi.nlm.nih.gov/pubmed/27248168

(28.)

Wallerius M, Wallmann T, Bartish M, Östling J, Mezheyeuski A, Tobin NP, Nygren E, Pangigadde P, Pellegrini P, Squadrito M L, Pontén F, Hartman J, Bergh J, De Milito A, Palma M, Ostman A, Andersson J, and Rolny C. SEMA3A restricts tumor growth by differentially regulating proliferation of pro- and anti-tumoral macrophages.

Cancer Res. 2016 Jun 1;76(11):3166-78

http://www.ncbi.nlm.nih.gov/pubmed/27197153

(27.)

Stålhammar G, Martinez N F, Lippert M, Tobin N P, Mølholm I, Kis L, Rosin G, Rantalainen M, Pedersen L, Bergh J, Grunkin M and Hartman J.

Digital image analysis outperforms manual biomarker assessment in breast cancer.

Mod Pathol. 2016 Apr;29(4):318-29

http://www.ncbi.nlm.nih.gov/pubmed/26916072

(26.)

Karthik GM, Ma R, Lövrot J, Kis LL, Lindh C, Blomquist L, Fredriksson I, Bergh J, Hartman J.

mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells.

Cancer Lett. 2015 Oct 10;367(1):76-87 http://www.ncbi.nlm.nih.gov/pubmed/26208432

(25.)

Stålhammar G, Farrajota P, Olsson A, Silva C, Hartman J, Elmberger G.

Gene protein detection platform-a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.

Ann Diagn Pathol. 2015 Aug;19(4):203-10 http://www.ncbi.nlm.nih.gov/pubmed/25921313

(24.)

Hong JW, Tobin NP, Rundqvist H, Li T, Lavergne M, Qin H, Paulsson J, Zeitelhofer M, Adzemovic M, Nilsson I, Roswall P, Hartman J, Johnson RS, Östman A, Bergh J, Poljakovic M and Genové G.

Tumor pericytes regulate myeloid-derived suppressor cell recruitment via IL-6.

J Natl Cancer Inst. 2015 Aug 21;107(10).

http://www.ncbi.nlm.nih.gov/pubmed/26296362

(23.)

Haglund F, Rosin G, Nilsson IL, Juhlin CC, Pernow Y, Norenstedt S, Dinets A, Larsson C, Hartman J, Höög A.

Tumour nuclear oestrogen receptor beta 1 correlates inversely with parathyroid tumour weight.

Endocr Connect. 2015 Mar;4(1):76-85. http://www.ncbi.nlm.nih.gov/pubmed/25648860

(22.)

Wang J, Cao Z, Zhang X, Nakamura M, Sun M, Hartman J, Harris RA, Sun Y, Cao Y.

Novel mechanism of macrophage-mediated metastasis revealed in a zebrafish model of tumor development.

Cancer Res. 2015 Jan 15;75(2):306-15. http://www.ncbi.nlm.nih.gov/pubmed/25492861

(21.)

Rosin G, de Boniface J, Karthik GM, Frisell J, Bergh J, Hartman J.

Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis.

Br J Cancer. 2014 Aug 26;111(5):918-26. http://www.ncbi.nlm.nih.gov/pubmed/25025959

(20.)

Klevebring D, Rosin G, Ma R, Lindberg J, Czene K, Kere J, Fredriksson I, Bergh J, Hartman J.

Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo.

Breast Cancer Res. 2014 Jul 6;16(4):R72.

http://www.ncbi.nlm.nih.gov/pubmed/24998755

(19.)

Wang J, Tsouko E, Jonsson P, Bergh J, Hartman J, Aydogdu E, Williams C.

miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer.

Cancer Res. 2015 Jan 15;75(2):306-15.

http://www.ncbi.nlm.nih.gov/pubmed/25074552

(18.)

Mojallal M, Zheng Y, Hultin S, Audebert S, van Harn T, Johnsson P, Lenander C, Fritz N, Mieth C, Corcoran M, Lembo F, Hallström M, Hartman J, Mazure NM, Weide T, Grandér D, Borg JP, Uhlén P, Holmgren L.

AmotL2 disrupts apical-basal cell polarity and promotes tumour invasion.

Nat Commun. 2014 Aug 1;5:4557

http://www.ncbi.nlm.nih.gov/pubmed/25080976

 

(17.)

Ma R, Fredriksson I, Karthik GM, Winn G, Darai-Ramqvist E, Bergh J, Hartman J.

Superficial scrapings from breast tumors is a source for biobanking and research purposes.

Lab Invest. 2014 Jul;94(7):796-805.

http://www.ncbi.nlm.nih.gov/pubmed/24776644

 

(16.)

Stålhammar G, Rosin G, Fredriksson I, Bergh J, Hartman J.

Low concordance of biomarkers in histopathological and cytological material from breast cancer.

Histopathology. 2014 Jun;64(7):971-80.

http://www.ncbi.nlm.nih.gov/pubmed/24320941

(15.)

Rubio CA, Ásmundsson J, Silva P, Illies C, Hartman J, Kis L.

Lymphoid aggregates in Crohn’s colitis and mucosal immunity.

Virchows Arch. 2013 Nov;463(5):637-42.

http://www.ncbi.nlm.nih.gov/pubmed/23979405

(14.)

Taher C, de Boniface J, Mohammad AA, Religa P, Hartman J, Yaiw KC, Frisell J, Rahbar A, Söderberg-Naucler C.

High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes.

PLoS One. 2013;8(2):e56795.

http://www.ncbi.nlm.nih.gov/pubmed/23451089

(13.)

Dey P, Jonsson P, Hartman J, Williams C, Ström A, Gustafsson JÅ.

Estrogen receptors β1 and β2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3.

Mol Endocrinol. 2012 Dec;26(12):1991-2003.

http://www.ncbi.nlm.nih.gov/pubmed/23028063

(12.)

Haglund F, Ma R, Huss M, Sulaiman L, Lu M, Nilsson IL, Höög A, Juhlin CC, Hartman J, Larsson C.

Evidence of a functional estrogen receptor in parathyroid adenomas.

J Clin Endocrinol Metab. 2012 Dec;97(12):4631-9.

http://www.ncbi.nlm.nih.gov/pubmed/23024189

(11.)

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

J Clin Oncol. 2012 Jul 20;30(21):2601-8.

http://www.ncbi.nlm.nih.gov/pubmed/22711854

(10.)

Rosin G, Hannelius U, Lindström L, Hall P, Bergh J, Hartman J*, Kere J*.

The dyslexia candidate gene DYX1C1 is a potential marker of poor survival in breast cancer.

BMC Cancer. 2012 Feb 29;12:79. *Delat författarskap

http://www.ncbi.nlm.nih.gov/pubmed/22375924

(9.)

Horimoto Y, Hartman J, Millour J, Pollock S, Olmos Y, Ho KK, Coombes RC, Poutanen M, Mäkelä SI, El-Bahrawy M, Speirs V, Lam EW.

ERβ1 represses FOXM1 expression through targeting ERα to control cell proliferation in breast cancer.

Am J Pathol. 2011 Sep;179(3):1148-56

http://www.ncbi.nlm.nih.gov/pubmed/21763263

(8.)

Millour J, Constantinidou D, Stavropoulou AV, Wilson MS, Myatt SS, Kwok JM, Sivanandan K, Coombes RC, Medema RH, Hartman J, Lykkesfeldt AE, Lam EW. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.

Oncogene. 2010 May 20;29(20):2983-95.

http://www.ncbi.nlm.nih.gov/pubmed/20208560

(7.)  *

Hartman J, Lam EW, Gustafsson JA, Ström A.

Hes-6, an inhibitor of Hes-1, is regulated by 17beta-estradiol and promotes breast cancer cell proliferation.

Breast Cancer Res. 2009;11(6):R79.

http://www.ncbi.nlm.nih.gov/pubmed/19891787

(6.) *

Hartman J, Edvardsson K, Lindberg K, Zhao C, Williams C, Ström A, Gustafsson JA.

Tumor repressive functions of estrogen receptor beta in SW480 colon cancer cells.

Cancer Res. 2009 Aug 1;69(15):6100-6

http://www.ncbi.nlm.nih.gov/pubmed/19602591

(5.)

Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK, Filipovic A, Gojis O, Palmieri C, Peston D, Shousha S, Yu Q, Sicinski P, Coombes RC, Lam EW.

FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer.

Int J Oncol. 2009 Jul;35(1):57-68.

http://www.ncbi.nlm.nih.gov/pubmed/19513552

(4.) *

Hartman J, Lindberg K, Morani A, Inzunza J, Ström A, Gustafsson JA.

Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts.

Cancer Res. 2006 Dec 1;66(23):11207-13.

http://www.ncbi.nlm.nih.gov/pubmed/17145865

(3.) *

Hartman J, Müller P, Foster JS, Wimalasena J, Gustafsson JA, Ström A.

HES-1 inhibits 17beta-estradiol and heregulin-beta1-mediated upregulation of E2F-1.

Oncogene. 2004 Nov 18;23(54):8826-33.

http://www.ncbi.nlm.nih.gov/pubmed/15467735

(2.) *

Ström A, Hartman J, Foster JS, Kietz S, Wimalasena J, Gustafsson JA.

Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D.

Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1566-71.

http://www.ncbi.nlm.nih.gov/pubmed/14745018

(1.)

Lewitt MS, Brismar K, Ohlson J, Hartman J.

Lithium chloride inhibits the expression and secretion of insulin-like growth factor-binding protein-1.

J Endocrinol. 2001 Dec;171(3):R11-5.

http://www.ncbi.nlm.nih.gov/pubmed/11739024

List of general articles

 

(8.) Review article

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Hudeček J, Voorwerk L, van Seijen M et al; International Immuno-Oncology Biomarker Working Group.

NPJ Breast Cancer. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1.

https://pubmed.ncbi.nlm.nih.gov/32436923/

 

(7.) Review article

Acs B, Rantalainen M, Hartman J.

Artificial intelligence as the next step towards precision pathology

Journal of Internal Medicine, in press.

https://onlinelibrary.wiley.com/doi/full/10.1002/path.5343

(6.) Review article

Acs B, Hartman J.

Next Generation Pathology: Artificial Intelligence Enhances Histopathology Practice.

J Pathol. 2019 Aug 29. doi: 10.1002/path.5343.

https://www.ncbi.nlm.nih.gov/pubmed/31465119

(5.) Review article

Robertson S, Azizpour H, Smith K, Hartman J.

Digital image analysis in breast pathology-from image processing techniques to artificial intelligence.

Transl Res. 2017 Nov 7. pii: S1931-5244(17)30295-5.

https://www.ncbi.nlm.nih.gov/pubmed/29175265

(4.) Review article

Hartman J, Ström A, Gustafsson JÅ.

Current concepts and significance of estrogen receptor β in prostate cancer.

Steroids. 2012 Oct;77(12):1262-6.

http://www.ncbi.nlm.nih.gov/pubmed/22824289

(3.) Review article

Hartman J, Gustafsson JA.

Estrogen receptors in colorectal cancer: goalkeepers, strikers, or bystanders?

Cancer Prev Res. 2010 Aug;3(8):897-9

http://www.ncbi.nlm.nih.gov/pubmed/20663982

(2.) Review article

Hartman J, Ström A, Gustafsson JA.

Estrogen receptor beta in breast cancer–diagnostic and therapeutic implications.

Steroids. 2009 Aug;74(8):635-41

http://www.ncbi.nlm.nih.gov/pubmed/19463683

(1.) Review article

Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JA.

Estrogen receptors: how do they signal and what are their targets.

Physiol Rev. 2007 Jul;87(3):905-31. Review.

http://www.ncbi.nlm.nih.gov/pubmed/17615392


List of review articles

(8.) Review article

Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.

Hudeček J, Voorwerk L, van Seijen M et al; International Immuno-Oncology Biomarker Working Group.

NPJ Breast Cancer. 2020 May 12;6:15. doi: 10.1038/s41523-020-0155-1.

https://pubmed.ncbi.nlm.nih.gov/32436923/


(7.) Review article

Acs B, Rantalainen M, Hartman J.

Artificial intelligence as the next step towards precision pathology

Journal of Internal Medicine, in press.

https://onlinelibrary.wiley.com/doi/full/10.1002/path.5343


(6.) Review article

Acs B, Hartman J.

Next Generation Pathology: Artificial Intelligence Enhances Histopathology Practice.

J Pathol. 2019 Aug 29. doi: 10.1002/path.5343.

https://www.ncbi.nlm.nih.gov/pubmed/31465119


(5.) Review article

Robertson S, Azizpour H, Smith K, Hartman J.

Digital image analysis in breast pathology-from image processing techniques to artificial intelligence.

Transl Res. 2017 Nov 7. pii: S1931-5244(17)30295-5.

https://www.ncbi.nlm.nih.gov/pubmed/29175265


(4.) Review article

Hartman J, Ström A, Gustafsson JÅ.

Current concepts and significance of estrogen receptor β in prostate cancer.

Steroids. 2012 Oct;77(12):1262-6.

http://www.ncbi.nlm.nih.gov/pubmed/22824289


(3.) Review article

Hartman J, Gustafsson JA.

Estrogen receptors in colorectal cancer: goalkeepers, strikers, or bystanders?

Cancer Prev Res. 2010 Aug;3(8):897-9

http://www.ncbi.nlm.nih.gov/pubmed/20663982


(2.) Review article

Hartman J, Ström A, Gustafsson JA.

Estrogen receptor beta in breast cancer–diagnostic and therapeutic implications.

Steroids. 2009 Aug;74(8):635-41

http://www.ncbi.nlm.nih.gov/pubmed/19463683


(1.) Review article

Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JA.

Estrogen receptors: how do they signal and what are their targets.

Physiol Rev. 2007 Jul;87(3):905-31. Review.

http://www.ncbi.nlm.nih.gov/pubmed/17615392


Copyright by Hartman Lab. All rights reserved.